Obesity – overview of contemporary knowledge and its role in the context of selected cardiovascular diseases
Authors:
Jakub Jurica 1; Martin Jozef Péč 1; Monika Péčová 2; Boris Focko 1; Tomáš Bolek 1; Patrícia Kleinová 1,3; Matej Samoš 1; Marián Mokáň 1
Authors‘ workplace:
I. interná klinika JLF UK a UNM, Martin
1; Národné centrum hemostázy a trombózy KHaT, JLF UK a UNM, Martin
2; Transplantačno–nefrologické oddelenie UNM, Martin
3
Published in:
Forum Diab 2024; 13(2): 96-101
Category:
Review Article
Overview
Obesity is a chronic metabolic disease, which is currently regarded as a new pandemic with a significant impact on the morbidity and mortality of population, while its prevalence is rising at an alarming rate. It is associated with cardiovascular diseases such as atrial fibrillation, syndrome of chronic heart failure as well as arterial hypertension. Even though the diagnostic process of obesity has not changed, and the value of Body mass index is still the main criterion, therapy has made significant progress incorporating new pharmacological agents including glucagon like peptide 1 receptor agonists. Clinical management of obese patients is still insufficient at present and receives little attention, it is usually initiated in late stages when complications have already developed, although clinical care for obese patients is not restricted to the obesitologist or endocrinologist/diabetologist, but it can be also managed by internists and general practitioners. Only a small percentage of patients with obesity receives recommended therapy and even fewer patients are followed up long-term on a regular basis to maintain the decreased weight. The aim of this article is to provide an insight into obesity as an independent disease with its own complications, diagnostic and therapeutic algorithm in the light of new evidence and to highlight the role of obesity and its specific features in the context of selected cardiovascular diseases.
Keywords:
obesity – cardiovascular diseases – glucagon like peptide 1 receptor agonists
Sources
Wang W, Wei PL, Lee YC et al. Short-term results of laparoscopic mini-gastric bypass. Obes Surg 2005; 15(5): 648–654. Dostupné z DOI: <http://dx.doi.org/10.1381/0960892053923752>.
Abdelaal M, Le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med 2017; 5(7): 161. Dostupné z DOI: <http://dx.doi.org/10.21037/atm.2017.03.107>.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1–253.
Bowman K, Atkins JL, Delgado J et al. Central adiposity and the overweight risk paradox in aging: follow-up of 130,473 UK Biobank participants. Am J Clin. Nutr 2017; 106(1): 130–135. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.116.147157>.
Di Lorenzo N, Antoniou SA, Batterham RL et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surg Endosc 2020; 34(6): 2332–2358. Dostupné z DOI: <http://dx.doi.org/10.1007/s00464–020–07555-y>.
Wharton S, Kuk JL, Luszczynski M et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery. Clin Obes 2019; 9(4): e12323. Dostupné z DOI: <http://dx.doi.org/10.1111/cob.12323>.
Fábryová Ľ. Prítomnosť a blízka budúcnosť farmakologickej liečby obezity/diabezity. Forum Diab 2022; 11(3): 135–142.
Fábryová Ľ (Ed) et al. Štandardné diagnostické a terapeutické postupy v manažmente obézneho jedinca. MZSR 2021. Dostupné z www: <https://www.health.gov.sk./?Standardne-Postupy-V-Zdravotnictve>.
Pi-Sunyer X, Astrup A, Fujioka K et al. [SCALE Obesity and Prediabetes NN8022–1839 Study Group]. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373(1):11–22. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1411892>.
Wilding JPH, Batterham RL, Calanna S et al. [STEP 1 Study Group]. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384(11): 989–1002. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2032183>.
Irfan H. Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial. Curr Probl Cardiol 2024; 49(1 Pt A): 102060. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cpcardiol.2023.102060>.
Eisenberg D, Shikora SA, Aarts E et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg 2023; 33(1): 3–14. Dostupné z DOI: <http://dx.doi.org/10.1007/s11695–022–06332–1>.
Welbourn R, Hollyman M, Kinsman R et al. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg 2019; 29(3): 782–795. Dostupné z DOI: <http://dx.doi.org/10.1007/s11695–018–3593–1>.
Holéczy P, Pekař M, Bužga M et al. Nové trendy súčasnej bariatricko-metabolickej chirurgie a ich prínos pre liečbu (pre)diabetu. Forum Diab 2022; 11(3): 143–150.
Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011; 13(Suppl 2): ii13–ii17. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/eur081>.
Roger VL, Go AS, Lloyd-Jones DM et al. [American Heart Association Statistics Committee and Stroke Statistics Subcommittee]. Heart Disease and Stroke Statistics-2011 Update: A Report from the American Heart Association. Circulation 2011; 123(4): e18–209. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0b013e3182009701>.
Zamora E, Lupon J, De Antonio M et al. Obesity paradox in heart failure with mid-range ejection fraction. Eur Heart J 2019; 40(1): ehz746.0927. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz746.0927>.
Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347(5): 305–313. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa020245>.
Glenn DJ, Wang F, Nishimoto M et al. A Murine Model of Isolated Cardiac Steatosis Leads to Cardiomyopathy. Hypertension 2011; 57(2): 216–222. Dostupné z DOI: <http://dx.doi.org/10.1161/hypertensionaha.110.160655>.
Ashrafian H, le Roux CW, Darzi A etg al. Effects of Bariatric Surgery on Cardiovascular Function. Circulation 2008; 118(20): 2091–2102. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.721027>.
Gosman GG, Katcher HI, Legro RS. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update 2006; 12: 585–601. Dostupné z DOI: <http://dx.doi.org/10.1093/humupd/dml024>.
Sarzani R, Salvi F, Dessi-Fulgheri P et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26(5): 831–843. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e3282f624a0>.
Grundy SM, Brewer Jr HB, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24(2): e13-e18. Dostupné z DOI: <http://dx.doi.org/10.1161/01.ATV.0000111245.75752.C6>
McDonagh TA, Metra M, Adamo M et al. [ESC Scientific Document Group]. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–3726. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab368>.
Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. [STEP-HFpEF Trial Committees and Investigators]. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023; 389(12): 1069–1084. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2306963>.
Vyas V, Lambiase P. Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities. Arrhythm Electrophysiol Rev 2019; 8(1): 28–36. Dostupné z DOI: <http://dx.doi.org/10.15420/aer.2018.76.2>.
Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the atherosclerosis risk in communities (ARIC) study. Circulation 2011; 123(14): 1501–1508. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.009035>.
Foy AJ, Mandrola J, Liu G et al. Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults. Am J Cardiol. 2018; 121(9): 1072–1075. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2018.01.019>.
Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg 2003; 13(5): 676–683. Dostupné z DOI: <http://dx.doi.org/10.1381/096089203322509228>.
Al Chekakie MO, Welles CC, Metoyer R et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010; 56(10): 784–788. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.03.071>.
Qu YC, Du YM, Wu SL et al. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43(5): 292–297. Dostupné z DOI: <http://dx.doi.org/10.1080/14017430802651803>.
Chung MK, Eckhardt LL, Chen LY et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement from the American Heart Association. Circulation 2020; 141(16): e750–e772. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000748>.
Pathak RK, Elliott A, Middeldorp ME et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015; 66(9):985–996. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.06.488>.
Qureshi WT, Alirhayim Z, Blaha MJ et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry ford exercise testing (FIT) project. Circulation 2015; 131(21): 1827–1834. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014833>.
Jamaly S, Carlsson L, Peltonen M et al. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 2016; 68(23): 2497–2504. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.09.940>.
Krahulec B, Fábryová Ľ, Holéczy P, Klimeš I (eds) et al. Klinická obezitológia. Facta Medica: Brno 2013. ISBN 978–80–904731–7-1.
Fábryová Ľ, Holéczy P (eds) et al. DIABEZITA. Diabetes a obezita: nerozlučné dvojičky. Facta Medica, Brno 2019. ISBN 978–80–88056–09–6.
Fábryová Ľ (ed) et al. Klinická obezitológia. Facta Medica, Brno 2023. ISBN 978–80–88056–16–4.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2024 Issue 2
Most read in this issue
- Transplantation of the islets of Langerhans – present and future. First experience with islet of Langerhans transplantation in Slovakia
- Obesity – overview of contemporary knowledge and its role in the context of selected cardiovascular diseases
- Actual position of metformin in the treatment of type 2 diabetes mellitus
- Chronic kidney disease in the context of diabetes mellitus